Stereotactic ablative radiotherapy for unresectable hepatocellular carcinoma patients who failed or were unsuitable for transarterial chemoembolization

• DOI: 10.1097/meg.0000000000000032
• Publication Date: 2014-01-01T08:15:54Z
• Authors: Cheng-Hsiang Lo; Wen-Yen Huang; Meei-Shyuan Lee; Kun-Tze Lin; Te-Pao Lin; Ping-Ying Chang; Chao-Yueh Fan; Yee-Min Jen
• Keywords: Cyberknife; Refractory (planetary science); Ablative case

The role of stereotactic ablative radiotherapy (SABR) in patients with hepatocellular carcinoma (HCC) who are refractory to or unsuitable for transarterial chemoembolization remains unclear. We examined the efficacy and safety Cyberknife SABR its effect on survival this group HCC patients.From June 2008 2011, 53 68 tumors unresectable were treated using SABR. measured 1.1-13 cm (median, 4.3 cm). median prescribed dose was 40 Gy four five fractions over 4-5 consecutive working days.The follow-up period 13.1 months all 18.1 living patients. Objective responses observed 48 67 (71.6%), including 22 (32.8%) complete responses. 1- 2-year in-field failure-free rate 73.3 66.8%, respectively. Out-field intrahepatic recurrence main cause treatment failure (28/52 patients). time 20.0 months, overall 70.1 45.4%, Multivariable analysis showed that Eastern Cooperative Oncology Group performance status (≤1 vs. >1) tumor response (responder nonresponder) independent prognostic factors survival. Radiation-induced liver disease, classic nonclassic types, developed (9.4%). Other acute toxicities generally mild tolerable.Our findings supported feasibility as a salvage when ineffective technically unsuitable. Additional efforts improve reduce out-field required.